Loading...
News2017-07-15T01:04:34-06:00

Categories

Archives

PRESS RELEASE: IVI Convenes First-of-its-Kind Multi-Stakeholder Summit to Accelerate Aligning Value Assessment Methods with Real-World Decision Needs

Participants Define Consensus Expectations and Prioritize Research Agenda to Improve Value Assessment Methods Alexandria, VA – March 17, 2020 – The Innovation and Value Initiative (IVI), a research-based non-profit improving the science and practice of [...]

March 17th, 2020|IVI News, Press|

PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer

IVI is thrilled to announce Pat Deverka, MD has joined our organization as our first Chief Science Officer. Dr. Deverka. Dr. Deverka brings to IVI more than three decades of experience in health economic [...]

February 4th, 2020|IVI News, Press|

PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment [...]

January 7th, 2020|IVI News, Press|

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions [...]

December 10th, 2019|IVI News, Press|

IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge

As one of the nine finalists in HealthEconomics.com's inaugural challenge competition to accelerate change in health economics and outcomes research, IVI's Mark Linthicum offered a compelling case for how IVI's Open-Source Value Platform (OSVP) is [...]

December 5th, 2019|IVI News|

IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA

IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling [...]

November 13th, 2019|IVI News, Viewpoints|

Jennifer Bright Explains How IVI Economic Models Improve Process of Value Assessment

At the National Health Council's event, Back to School: Patient Community Training on Value Assessment, IVI executive director Jennifer Bright explains the non-profit organization's mission to make value assessment more relevant to real decision making, [...]

November 8th, 2019|Events, IVI News|